Arch manangement announced on X yesterday that it will be presenting at 2 conferences starting Oct 23 in San Diego California and in November in Stockholm Sweden.
Now one thing we know is Arch CEO is extremely frugal with his operating budget and the company does not have a history of presenting at these type of target rich events.
As we delve a little deeper we know Arch has raised almost $1M new capital in the past 3 months and they have been dosing at 5 sites in Turkey for 8 months. I believe this money was raised to get Arch across tge finish line!
Arch management has provided zero updates on the progress of dosing in Turkey with ultimate goal of 240 patients.
Now one cannot imagine that Arch would attend these two premiere conferences that will have a target rich audience with many of the top industry analysts, Institutional Investors and Big Pharma Executives attending if they did not have compelling data to present. This my friends is the TSN turning point. We currently have zero Institutional Investors and no analydts after RJ analalyst left the firm, this will be changing very soon.
In my humble opinion I believe this is a huge turning point for Arch and this clearly signals that the phase 2 trial in Turkey is close to wrapping up after 8 months of dosing with zero adverse reactions.
Good luck to all the longs, 2025 is going to reward those who stuck it out!!!
https://x.com/archbiopartners/status/1846613349775106184